Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 88 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Review, H1 2016', provides an overview of the Primary Progressive Multiple Sclerosis (PPMS) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Progressive Multiple Sclerosis (PPMS) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Primary Progressive Multiple Sclerosis (PPMS)
- The report reviews pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Primary Progressive Multiple Sclerosis (PPMS) therapeutics and enlists all their major and minor projects
- The report assesses Primary Progressive Multiple Sclerosis (PPMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Primary Progressive Multiple Sclerosis (PPMS)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Primary Progressive Multiple Sclerosis (PPMS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Primary Progressive Multiple Sclerosis (PPMS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Primary Progressive Multiple Sclerosis (PPMS) Overview 6
Therapeutics Development 7
Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) - Overview 7
Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics under Development by Companies 8
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Primary Progressive Multiple Sclerosis (PPMS) - Products under Development by Companies 11
Primary Progressive Multiple Sclerosis (PPMS) - Companies Involved in Therapeutics Development 12
AB Science SA 12
F. Hoffmann-La Roche Ltd. 13
Genzyme Corporation 14
Kyorin Pharmaceutical Co., Ltd. 15
MedDay 16
Santhera Pharmaceuticals Holding AG 17
Teva Pharmaceutical Industries Limited 18
Primary Progressive Multiple Sclerosis (PPMS) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
ApE - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
biotin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
GZ-402668 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ibudilast - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
idebenone - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
laquinimod sodium - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
masitinib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ocrelizumab - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Stem Cell Therapy for CNS Disorders - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Primary Progressive Multiple Sclerosis (PPMS) - Recent Pipeline Updates 50
Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects 79
Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products 80
Primary Progressive Multiple Sclerosis (PPMS) - Product Development Milestones 81
Featured News & Press Releases 81
Feb 17, 2016: FDA Grants Breakthrough Therapy Designation for Genentech's Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis 81
Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 81
Oct 10, 2015: More Results Released from Positive Phase III Clinical Trial of Ocrelizumab in Primary Progressive MS 83
Apr 23, 2015: Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS 84
Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 85
Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC 85
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88

List of Tables

Number of Products under Development for Primary Progressive Multiple Sclerosis (PPMS), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by AB Science SA, H1 2016 12
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 13
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Genzyme Corporation, H1 2016 14
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 15
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by MedDay, H1 2016 16
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2016 17
Primary Progressive Multiple Sclerosis (PPMS) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Primary Progressive Multiple Sclerosis (PPMS) Therapeutics - Recent Pipeline Updates, H1 2016 50
Primary Progressive Multiple Sclerosis (PPMS) - Dormant Projects, H1 2016 79
Primary Progressive Multiple Sclerosis (PPMS) - Discontinued Products, H1 2016 80